title: Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.
authors.affiliation: Department of Emergency Medicine, University of Michigan, Ann Arbor, USA. phlsctt@med.umich.edu
authors.forename: Phillip A
authors.initials: PA
authors.lastname: Scott
authors.forename: Shirley M
authors.initials: SM
authors.lastname: Frederiksen
authors.forename: John D
authors.initials: JD
authors.lastname: Kalbfleisch
authors.forename: Zhenzhen
authors.initials: Z
authors.lastname: Xu
authors.forename: William J
authors.initials: WJ
authors.lastname: Meurer
authors.forename: Angela F
authors.initials: AF
authors.lastname: Caveney
authors.forename: Annette
authors.initials: A
authors.lastname: Sandretto
authors.forename: Ann B
authors.initials: AB
authors.lastname: Holden
authors.forename: Mary N
authors.initials: MN
authors.lastname: Haan
authors.forename: Ellen G
authors.initials: EG
authors.lastname: Hoeffner
authors.forename: Sameer A
authors.initials: SA
authors.lastname: Ansari
authors.forename: David P
authors.initials: DP
authors.lastname: Lambert
authors.forename: Michael
authors.initials: M
authors.lastname: Jaggi
authors.forename: William G
authors.initials: WG
authors.lastname: Barsan
authors.forename: Robert
authors.initials: R
authors.lastname: Silbergleit
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000379:methods* / Q000592:standards*; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000401:mortality; D015331:Cohort Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D004635:Emergency Medicine / Q000592:standards; D004636:Emergency Service, Hospital; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D016017:Odds Ratio; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016016:Proportional Hazards Models; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator